

in micronized form or comiconized form with one or more pharmaceutically acceptable excipients.

45. Pharmaceutical compositions comprising one or more compounds of the formula (I) as defined in Claim 22, in combination with a compound which has agonist activity on the CB2 receptor of cannabinoids and with pharmaceutically acceptable excipients.

46. Pharmaceutical composition according to Claim 45, in which the said compounds with agonist activity on the CB2 receptor of cannabinoids are ALIAMides.

47. Pharmaceutical compositions according to Claim 45, in which the compounds are present in micronized form or comiconized form with one or more pharmaceutically acceptable excipients.

48. Pharmaceutical compositions according to Claim 46, in which the compounds are present in micronized form or comiconized form with one or more pharmaceutically acceptable excipients.

49. Kit for simultaneous, sequential or separate administration, comprising one or more compounds of formula (I), as defined in Claim 22, and a compound with agonist activity on the CB2 receptor of cannabinoids, in suitable pharmaceutical formulations.

50. Kit according to Claim 49, in which the compounds are present in micronized form or comiconized form with one or more pharmaceutically acceptable excipients.--

REMARKS

The above amendments are made to place the claims in a more traditional format.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: Frank P. Presta

Frank P. Presta
Reg. No. 19,828

FPP:ms
1100 North Glebe Road, 8th Floor
Arlington, VA 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100